Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCEH1 | Q6PIU2 | 3/20 | 0.43 |
| ▸ | KCNJ11 | Q14654 | 5/20 | 0.39 |
| ▸ | ABCC9 | O60706 | 3/20 | 0.39 |
| ▸ | ABCC8 | Q09428 | 3/20 | 0.39 |
| ▸ | KCNJ8 | Q15842 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.34 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL808968 | 0.80 | HDAC3 (0.47) | KCNJ11MEN1KMT2AHDAC3CYP2C9 | |
| SCHEMBL809232 | 0.76 | ALDH1A1 (0.41) | NCEH1KCNJ11MEN1KMT2A | |
| SCHEMBL808813 | 0.75 | MEN1 (0.43) | NCEH1KCNJ11ABCC9ABCC8KCNJ8 | |
| SCHEMBL808828 | 0.74 | PDK1 (0.37) | KCNJ11 | |
| SCHEMBL809275 | 0.74 | PDK1 (0.37) | — | |
| SCHEMBL808979 | 0.74 | NCEH1 (0.42) | NCEH1MEN1KMT2ACYP2C9 | |
| SCHEMBL808782 | 0.74 | NCEH1 (0.42) | NCEH1MEN1KMT2ACYP2C9 | |
| SCHEMBL808837 | 0.72 | ALDH1A1 (0.43) | NCEH1MEN1KMT2ACYP2C9MTNR1A | |
| SCHEMBL809068 | 0.71 | PLK1 (0.41) | MEN1KMT2ACYP2C9 | |
| SCHEMBL808840 | 0.71 | METAP2 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1593674-B1 | OPTICALLY ACTIVE BISOXAZOLINE COMPOUNDS, PROCESS FOR PRODUCTION OF THE SAME AND USE THEREOF | SUMITOMO CHEMICAL CO (JP) | 2011-07-20 | — | — | EP | disclosed |
| US-7683215-B2 | Optically active bisoxazoline compounds, process for production of the same and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-03-23 | — | — | US | disclosed |
| US-7671213-B2 | Optically active bisoxazoline compounds, process for production of the same and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-03-02 | — | — | US | disclosed |
| US-20080076931-A1 | OPTICALLY ACTIVE BISOXAZOLINE COMPOUNDS, PROCESS FOR PRODUCTION OF THE SAME AND USE THEREOF | ITAGAKI MAKOTO | 2008-03-27 | — | — | US | disclosed |
| US-20080076941-A1 | OPTICALLY ACTIVE BISOXAZOLINE COMPOUNDS, PROCESS FOR PRODUCTION OF THE SAME AND USE THEREOF | ITAGAKI MAKOTO | 2008-03-27 | — | — | US | disclosed |
| CN-101125833-A | Optically active bisoxazoline compounds, process for production of the same and use thereof | SUMITOMO CHEMICAL CO (JP) | 2008-02-20 | — | — | CN | disclosed |
| US-7288674-B2 | Optically active bisoxazoline compounds, process for production of the same and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2007-10-30 | — | — | US | disclosed |
| US-20060149077-A1 | Optically active bisoxazoline compounds, process for production of the same and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2006-07-06 | — | — | US | disclosed |
| CN-1771236-A | Optically active bisoxazoline compound, process for producing the same, and use thereof | SUMITOMO CHEMICAL CO (JP) | 2006-05-10 | — | — | CN | disclosed |
| EP-1593674-A1 | OPTICALLY ACTIVE BISOXAZOLINE COMPOUNDS, PROCESS FOR PRODUCTION OF THE SAME AND USE THEREOF | Sumitomo Chemical Company, Limited (JP) | 2005-11-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060149077-A1 | Optically active bisoxazoline compounds, process for production of the same and use thereof | ACSL3, ADSL, SQLE | NCEH1 1915/4885KCNJ11 1282/4885ABCC9 1300/4885 |
| US-20080076941-A1 | OPTICALLY ACTIVE BISOXAZOLINE COMPOUNDS, PROCESS FOR PRODUCTION OF THE SAME AND USE THEREOF | ACSL3, ADSL, SQLE | NCEH1 1915/4885KCNJ11 1282/4885ABCC9 1300/4885 |
| US-20080076931-A1 | OPTICALLY ACTIVE BISOXAZOLINE COMPOUNDS, PROCESS FOR PRODUCTION OF THE SAME AND USE THEREOF | ACSL3, ADSL, SQLE | NCEH1 1915/4885KCNJ11 1282/4885ABCC9 1300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.